The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksHigh Impact•10 March 2026•

1 min read

FDA Accuses uniQure of Data Manipulation for AMT-130; Legal Action Intensifies

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1The FDA reportedly accused uniQure of pushing 'distorted' and 'manipulated' data for its AMT-130 drug.

The U.S. Food and Drug Administration (FDA) has reportedly issued a severe rebuke against uniQure N.V., accusing the biotechnology firm of presenting "distorted" and "manipulated" clinical data. The allegations center on the company's experimental drug AMT-130, which federal health officials have characterized as a "failed" treatment. In response to these developments, the law firm Hagens Berman has announced an update to its ongoing investigation into a securities class action lawsuit against the company. The investigation seeks to determine whether uniQure misled investors regarding the efficacy and regulatory status of its key drug candidate. This regulatory scrutiny represents a significant blow to the company's credibility and its future prospects in the gene therapy market. Market analysts expect these accusations to exert substantial downward pressure on the stock as legal and regulatory risks escalate.